Absci Corporation (ABSI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABSI SEC filings page.
Absci Corporation (ABSI) reported $1.6M in revenue over the twelve months to Jun 30, 2026, down 62.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Absci remains a development-stage business: R&D dominates reported revenue, while external financing funds ongoing cash needs.
In FY2025, revenue fell to$2.8M while R&D reached$81.4M , so the larger loss reflects intensified development spending as commercial receipts weakened. Operating cash flow moved from-$72.4M to-$92.9M across FY2024-FY2025, confirming that the accounting loss was accompanied by a deeper cash requirement.
FY2025 liabilities were only
FY2025 financing provided
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Absci Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Absci Corporation held $156.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $92.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Absci Corporation scores 45/100 among other emerging companies.
Absci Corporation had 153M shares outstanding at the end of fiscal year 2025, against 127M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Absci Corporation scores 39/100 among other emerging companies.
Absci Corporation spent $81.4M on research and development in fiscal year 2025, which was 66.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Absci Corporation scores 88/100 among other emerging companies.
Absci Corporation reported revenue of $2.8M in fiscal year 2025, against $4.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Absci Corporation scores 13/100 among other emerging companies.
Absci Corporation's operations used $92.9M of cash in fiscal year 2025, against $72.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Absci Corporation scores 31/100 among other emerging companies.
Absci Corporation's cash, cash equivalents and investments came to $156.1M at the end of fiscal year 2025, against $26.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Absci Corporation scores 90/100 among other emerging companies.
Absci Corporation scores 28.36, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.5B) relative to total liabilities ($26.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Absci Corporation passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Absci Corporation reported a net loss of $115.2M while operations used $92.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Absci Corporation reported an operating loss of $120.3M against $209K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Absci Corporation generated $318K in revenue in Q2 2026. This represents a decrease of 46.4% from the same quarter a year earlier. Against the prior quarter it is up 47.9%.
Absci Corporation's EBITDA was -$31.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is down 11.9%.
Absci Corporation reported -$33.2M in net income in Q2 2026. This represents a decrease of 8.6% from the same quarter a year earlier. Against the prior quarter it is down 12.2%.
Absci Corporation earned -$0.21 per diluted share (EPS) in Q2 2026. This represents an increase of 12.5% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.
Cash & Balance Sheet
Absci Corporation recorded an outflow of $27.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 61.2% from the same quarter a year earlier. Against the prior quarter it is down 4.7%.
Absci Corporation held $107.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Absci Corporation's ROE was -13.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Absci Corporation invested $22.6M in research and development in Q2 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 17.3%.
Absci Corporation invested $1K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 99.6% from the same quarter a year earlier. Against the prior quarter it is down 96.7%.
Not reported for Q2 2026.
ABSI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $318K-46.4% | $215K-81.8% | $650K-2.3% | $378K-77.8% | $593K-53.3% | $1.2M+31.3% | $665K+96.7% | $1.7M+128.6% |
| R&D Expenses | $22.6M+10.5% | $19.3M+17.8% | $25.3M+37.9% | $19.2M+7.0% | $20.5M+34.1% | $16.4M+33.7% | $18.4M+49.8% | $18.0M+63.1% |
| SG&A Expenses | $9.2M+7.5% | $9.1M-4.4% | $8.6M-2.4% | $8.4M-8.8% | $8.5M-8.8% | $9.5M+8.3% | $8.8M-5.3% | $9.3M-2.6% |
| Operating Income | -$34.2M-8.8% | -$30.8M-11.2% | -$31.0M-4.3% | -$30.2M-4.4% | -$31.4M-17.5% | -$27.7M-18.0% | -$29.8M-20.4% | -$28.9M-24.0% |
| EBITDA | -$31.5M-10.8% | -$28.1M-14.0% | -$28.2M-6.3% | -$27.3M-6.9% | -$28.4M-21.7% | -$24.7M-22.8% | -$26.5M-24.9% | -$25.5M-29.1% |
| Interest Expense | $2K-96.4% | $18K-77.2% | $29K-73.4% | $45K-65.4% | $56K-62.7% | $79K-55.1% | $109K-46.6% | $130K-43.2% |
| Income Tax | $40K-69.5% | $18K+550.0% | -$162K-871.4% | $104K+181.1% | $131K | -$4K-133.3% | $21K-56.3% | $37K+8.8% |
| Net Income | -$33.2M-8.6% | -$29.6M-12.3% | -$29.6M-2.0% | -$28.7M-4.8% | -$30.6M-23.5% | -$26.3M-19.9% | -$29.0M-23.1% | -$27.4M-24.6% |
| EPS (Basic) | -$0.21+12.5% | -$0.19+9.5% | -$0.19+26.9% | -$0.20+16.7% | -$0.24-9.1% | -$0.21+4.5% | -$0.26-4.0% | -$0.240.0% |
| EPS (Diluted) | -$0.21+12.5% | -$0.19+9.5% | -$0.19+26.9% | -$0.20+16.7% | -$0.24-9.1% | -$0.21+4.5% | -$0.26-4.0% | -$0.240.0% |
| Diluted Shares (Avg) | 157M+23.4% | 153M+22.9% | N/A | 144M+26.5% | 128M+13.0% | 124M+25.2% | N/A | 114M+23.2% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
ABSI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $268.9M+28.1% | $195.6M-15.9% | $216.3M+1.3% | $245.0M+4.1% | $209.9M-17.9% | $232.4M-15.4% | $213.6M-1.7% | $235.2M-0.5% |
| Current Assets | $208.3M+51.6% | $132.0M-15.4% | $149.6M+11.8% | $175.0M+16.6% | $137.4M-16.8% | $156.0M-14.2% | $133.8M+11.0% | $150.1M+11.5% |
| Cash & Equivalents | $107.9M+183.7% | $8.6M-81.6% | $20.0M-51.4% | $9.5M-75.2% | $38.0M-11.4% | $47.0M-20.1% | $41.2M-43.0% | $38.2M-45.2% |
| Short-Term Investments | $93.3M | $117.1M | $124.3M+74.5% | $143.0M | $0 | $0 | $71.2M | $0 |
| Accounts Receivable | N/A | N/A | N/A | $1.0M | $700K | $1.4M | $0-100.0% | N/A |
| Long-Term Investments | $0 | $4.8M | $11.8M | $32.6M | $0 | $0 | $0 | $0 |
| Total Liabilities | $22.8M-37.6% | $23.6M-29.8% | $26.8M-22.1% | $34.7M+2.2% | $36.5M+7.3% | $33.7M-3.3% | $34.5M-16.2% | $33.9M-15.1% |
| Current Liabilities | $19.6M-37.4% | $20.0M-26.6% | $22.8M-20.6% | $29.7M+11.3% | $31.3M+23.0% | $27.3M+7.9% | $28.7M-3.1% | $26.7M-4.6% |
| Non-Current Liabilities | $3.2M-38.6% | $3.6M-43.6% | $4.1M-29.8% | $4.9M-31.4% | $5.2M-39.4% | $6.4M-33.0% | $5.8M-49.7% | $7.2M-39.7% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $4.0M-49.6% | N/A |
| Total Equity | $246.1M+42.0% | $172.0M-13.5% | $189.4M+5.8% | $210.3M+4.5% | $173.4M-21.7% | $198.8M-17.2% | $179.1M+1.7% | $201.3M+2.5% |
| Retained Earnings | -$687.6M-21.4% | -$654.4M-22.1% | -$624.8M-22.6% | -$595.2M-23.8% | -$566.5M-25.0% | -$535.9M-25.1% | -$509.6M-25.4% | -$480.6M-25.5% |
Not reported in any period shown, so not listed: Inventory, Goodwill.
ABSI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.6M-63.4% | -$26.3M-20.5% | -$29.2M-72.0% | -$25.0M-20.7% | -$16.9M-0.2% | -$21.8M-22.3% | -$17.0M-13.7% | -$20.7M-100.1% |
| Depreciation & Amortization | $2.7M-10.1% | $2.7M-11.2% | $2.8M-12.6% | $2.8M-15.3% | $3.0M-11.3% | $3.1M-10.1% | $3.2M-7.2% | $3.4M-4.5% |
| Stock-Based Compensation | $5.2M+10.4% | $4.4M-10.8% | N/A | $4.4M-20.2% | $4.8M-10.3% | $4.9M+36.9% | N/A | $5.5M+115.7% |
| Capital Expenditures | $1K-99.6% | $30K+20.0% | -$103K+347.8% | $962K+1904.2% | $223K-33.0% | $25K | $23K+35.3% | $48K-84.4% |
| Free Cash Flow | -$27.6M-61.2% | -$26.3M-20.5% | -$29.3M-72.4% | -$26.0M-25.1% | -$17.1M+0.5% | -$21.9M-22.4% | -$17.0M-13.7% | -$20.8M-94.8% |
| Investing Cash Flow | $24.1M+166.3% | $7.4M+148.9% | $19.5M+2.6% | -$63.7M-530.2% | $9.0M+620.2% | -$15.0M+80.4% | $19.0M+0.4% | $14.8M-26.5% |
| Financing Cash Flow | $102.7M+10331.7% | $7.6M-82.3% | $3.8M+289.7% | $60.3M+12209.6% | -$1.0M-649.3% | $42.8M-47.3% | $986K+179.8% | $490K+153.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ABSI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -10741.5% | -14347.0% | -4775.5% | -7977.2% | -5293.9% | -2351.9% | -4477.3% | -1698.7% |
| Net Margin | -10443.4% | -13767.0% | -4548.0% | -7594.2% | -5155.0% | -2234.6% | -4358.4% | -1610.7% |
| Return on Equity | -13.5%+4.1pp | -17.2%-4.0pp | -15.6%+0.6pp | -13.7%0.0pp | -17.6%-6.5pp | -13.3%-4.1pp | -16.2%-2.8pp | -13.6%-2.4pp |
| Return on Assets | -12.3%+2.2pp | -15.1%-3.8pp | -13.7%-0.1pp | -11.7%-0.1pp | -14.6%-4.9pp | -11.3%-3.3pp | -13.6%-2.7pp | -11.7%-2.3pp |
| Current Ratio | 10.63+6.2x | 6.59+0.9x | 6.57+1.9x | 5.89+0.3x | 4.39-2.1x | 5.72-1.5x | 4.67+0.6x | 5.63+0.8x |
| Debt-to-Equity | 0.09-0.1x | 0.140.0x | 0.14+0.1x | 0.160.0x | 0.21+0.1x | 0.170.0x | 0.020.0x | 0.170.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.000.0x | 0.010.0x |
| FCF Margin | -8668.2% | -12249.8% | -4505.4% | -6876.5% | -2883.0% | -1854.4% | -2554.4% | -1221.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Absci Corporation ABSI | FY2025 | $2.8M | -$115.2M | N/A | $1.5B | 51/100 |
| Inhibrx Biosciences, Inc. INBX | FY2025 | $1.3M | -$140.1M | N/A | $1.3B | 21/100 |
| Cullinan Therapeutics, Inc. CGEM | FY2025 | N/A | -$219.9M | N/A | $907.4M | — |
| Astria Therapeutics, Inc. ATXS | FY2024 | N/A | -$94.3M | N/A | $718.1M | — |
| Lexicon Pharmaceuticals, Inc. LXRX | FY2025 | $49.8M | -$50.3M | N/A | $716.4M | 65/100 |
| Y-mAbs Therapeutics, Inc. YMAB | FY2024 | $87.7M | -$29.7M | -33.8% | $391.2M | 71/100 |
Where Absci Corporation Ranks
Frequently Asked Questions
What is Absci Corporation's annual revenue?
Absci Corporation (ABSI) reported $2.8M in total revenue for fiscal year 2025. This represents a -38.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Absci Corporation's revenue growing?
Absci Corporation (ABSI) revenue declined by 38.2% year-over-year, from $4.5M to $2.8M in fiscal year 2025.
Is Absci Corporation profitable?
No, Absci Corporation (ABSI) reported a net income of -$115.2M in fiscal year 2025.
What is Absci Corporation's EBITDA?
Absci Corporation (ABSI) had EBITDA of -$108.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Absci Corporation's return on equity (ROE)?
Absci Corporation (ABSI) has a return on equity of -60.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Absci Corporation's free cash flow?
Absci Corporation (ABSI) recorded an outflow of $94.0M in free cash flow during fiscal year 2025. This represents a -29.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Absci Corporation's operating cash flow?
Absci Corporation (ABSI) recorded an outflow of $92.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Absci Corporation's total assets?
Absci Corporation (ABSI) had $216.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Absci Corporation's capital expenditures?
Absci Corporation (ABSI) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Absci Corporation spend on research and development?
Absci Corporation (ABSI) invested $81.4M in research and development during fiscal year 2025.
What is Absci Corporation's current ratio?
Absci Corporation (ABSI) had a current ratio of 6.57 as of fiscal year 2025, which is generally considered healthy.
What is Absci Corporation's debt-to-equity ratio?
Absci Corporation (ABSI) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Absci Corporation's return on assets (ROA)?
Absci Corporation (ABSI) had a return on assets of -53.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Absci Corporation's P/E ratio?
Absci Corporation (ABSI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Absci Corporation's price-to-sales ratio?
Absci Corporation (ABSI) trades at 961x sales, its market capitalization divided by revenue of $1.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Absci Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Absci Corporation (ABSI) held $156.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $92.9M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Absci Corporation's Altman Z-Score?
Absci Corporation (ABSI) has an Altman Z-Score of 28.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Absci Corporation's Piotroski F-Score?
Absci Corporation (ABSI) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Absci Corporation's earnings high quality?
Absci Corporation (ABSI) reported a net loss of $115.2M while operations used $92.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Absci Corporation cover its interest payments?
Absci Corporation (ABSI) reported an operating loss of $120.3M against $209K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Absci Corporation?
Absci Corporation (ABSI) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.